For Treatment Centers

Transform Early Autism Diagnosis and Objective Phenotyping with EarliPoint™

An Objective tool to measure social disability, verbal ability, and nonverbal learning while assisting with autism diagnosis in children under 3.

In early childhood, accurate and timely diagnosis is critical for ensuring that children with Autism Spectrum Disorder (ASD) and developmental delays receive the right interventions at the right time. However, traditional diagnostic methods often rely on subjective observations and can miss key signs, leading to delayed intervention and poor long-term outcomes.1,5 EarliPoint™ Evaluation System is the only FDA-cleared, objective tool that helps ABA, occupational, and speech therapy centers accurately assess children as young as 16 months.2-4 By measuring social disability, verbal ability, and non-verbal cognitive abilities, EarliPoint™ provides reliable, data-driven insights that enable early, accurate diagnoses and can help with effective treatment planning.3-4

Don’t wait until school age to intervene—start early, avoid the risks of delayed diagnosis, and provide children with the support they need to thrive.5

Watch this 1-minute EarliPoint™ overview video

The Challenge: Delays in Diagnosis and Missed Opportunities for Early Intervention

  • Delayed Diagnosis: Most children with ASD or developmental delays are not diagnosed until ages 4-5, missing the window for critical intervention during the most malleable period of brain development.1-2,5 Watchful waiting in hopes that children will “outgrow” their delays only leads to greater developmental challenges down the line. Early intervention is key to minimizing long-term costs and maximizing future independence.1,6,7

  • Missed Opportunities: The longer the delay in diagnosis, the harder it becomes to catch up developmentally. Delays in speech, social engagement, and motor skills often worsen if not addressed early.5 EP helps with early diagnosis, as young as 16 months…By using true eye-tracking technology, EarliPoint™ measures social disability, verbal ability, and non-verbal learning – critical areas for assessing early signs of ASD.1-3

  • The Risk of Misdiagnosis: With traditional diagnostic tools, like ADOS-2 and CARS-2, relying on subjective behavioral observations, there is a risk of misdiagnosis or failure to identify milder forms of ASD.1,5,8,9 This can lead to ineffective treatment plans and missed opportunities for early support.

  • Streamline Referrals: Early referral for speech therapy, occupational therapy, or ABA therapy is essential for children with developmental delays or ASD. EarliPoint™ can streamline the referral process, helping to ensure that children receive the interventions they need sooner, preventing delays that can lead to longer-term challenges in development.2-3

Get Objective Baseline Data for Accurate Therapy Planning with EarliPoint™

Therapy centers are often left with incomplete or unclear diagnosis referrals, forcing you to conduct your own evaluation before developing a therapy plan. This can delay treatment and lead to inconsistent results. EarliPoint™ provides objective, baseline phenotyping data on a child’s social disability, verbal ability, and non-verbal learning skills, giving therapists the insights they need to create accurate, data-driven treatment plans from the start.3-4

When a child with Autism Spectrum Disorder (ASD) is referred to your therapy center, the lack of a clear phenotyping baseline can make it difficult to develop a targeted therapy plan right away. Without clear data on the child’s social disability, verbal ability, and non-verbal cognitive skills, you’re left with uncertainty, possibly extending the time it takes for the child to begin receiving effective intervention.

With EarliPoint™, the only FDA-cleared, objective tool to aid in early autism assessment in children as young as 16 months, you can access reliable baseline data that highlights key areas of concern. This true eye-tracking technology provides clear, quantifiable measurements, allowing you to quickly understand a child’s social engagement and communication abilities.3-4 Armed with this data, you can develop a personalized therapy plan that targets the child’s specific needs, improving both the efficiency and effectiveness of your therapy sessions.

Streamline Referrals:

  • Early referral for speech therapy, occupational therapy, or ABA therapy is essential for children with developmental delays or ASD. EarliPoint™ can help streamline the referral process, ensuring that children receive the interventions they need sooner, preventing delays that can lead to longer-term challenges in development.

EarliPoint™ ensures that no child falls through the cracks due to incomplete data, enabling you to move from diagnosis to treatment efficinetly.3-4 Stop spending time guessing about where to start – start with the data that makes all the difference.

The Solution: EarliPoint™ Evaluation System — Early, Objective Diagnostic Data

EarliPoint™ is the only FDA-cleared tool designed to aid qualified clinicians in diagnosing ASD in children 16 months through 30 months, who are at risk based on concerns identified by a parent, caregiver, or healthcare provider.2-4 By using eye-tracking technology, EarliPoint™ provides objective measurements of social disability, verbal ability, and non-verbal learning skills, allowing therapists to make data-driven diagnoses that guide treatment planning.3-4 Relative to expert clinical diagnosis, in a double-blind study of 719 children aged 16 to 30 months, EarliPoint demonstrated an AUC diagnostic performance of 0.90 (1.0 is perfect). 3-4

Listen and watch what two ABA Chief Clinical Officers have to say about EarliPoint

Why ABA, Occupational, and Speech Therapy Centers Choose EarliPoint™

  1. FDA-Cleared, Objective Measurement:

    • EarliPoint™ is the only FDA-cleared tool designed to aid in the diagnoses of ASD in children as young as 16 months.2-4 By using eye-tracking technology, EarliPoint™ provides objective measurements of social disability, verbal ability, and non-verbal learning skills, allowing therapists to make data-driven diagnoses that guide treatment planning.3-4

  2. Proven Diagnostic Performance:

    • Relative to expert clinical diagnosis, in a double-blind study of 719 children aged 16 to 30 months, EarliPoint demonstrated a diagnostic performance of 0.9 (1.0 is perfect) in children as young as 16 months.3-4 EarliPoint™ aligns with expert clinical diagnoses, ensuring that you have the most reliable data to confidently assess children and guide them toward appropriate therapies.3-4

  3. Streamline Referrals and Intervention:

    • Early referral for speech therapy, occupational therapy, or ABA therapy is essential for children with developmental delays or ASD. EarliPoint™ streamlines the referral process, helping children receive the interventions they need sooner, preventing delays that can lead to longer-term challenges in development. 2-3

  4. Assess Development Over Time:

    • EarliPoint™ is not just for diagnosing, it’s also for ongoing assessments. By comparing future assessments with the initial evaluation or diagnostic baseline, you can measure a child’s progress over time and adjust treatment plans as needed.3-4 This allows therapists to track changes and adjust treatment plans, throughout their developmental journey.3-4

Take Action: Don’t Wait — Intervene Early with EarliPoint™

The longer you wait to diagnose autism, the harder it becomes to achieve the best outcomes for children. With EarliPoint™ as your diagnostic aid, you can provide early, objective diagnoses. Early diagnosis can lead to better long-term results.1,2,3  Don’t risk the costs and emotional strain of delayed intervention-start using EarliPoint™ today and transform your therapy practice.

Contact Us Today

References

1. Jones, W., Klaiman, C., Richardson, S., Lambha, M., Reid, M., Hamner, T., Beacham, C., Lewis, P., Paredes, J., Edwards, L., Marrus, N., Constantino, J. N., Shultz, S., & Klin, A. (2023). Development and Replication of Objective Measurements of Social Visual Engagement to Aid in Early Diagnosis and Assessment of Autism. JAMA Network Open, 6(9), e2330145.

2. Yu Y, Ozonoff S, Miller M. Assessment of Autism Spectrum Disorder. Assessment. 2024 Jan;31(1):24-41. doi: 10.1177/10731911231173089. Epub 2023 May 29. PMID: 37248660; PMCID: PMC10676043. https://pmc.ncbi.nlm.nih.gov/articles/PMC10676043/

3. Jones W, Klaiman C, Richardson S, et al. Eye-Tracking–Based Measurement of Social Visual Engagement Compared With Expert Clinical Diagnosis of Autism. 2023;330(9):854–865. doi:10.1001/jama.2023.13295

4. FDA-cleared tool could assist in diagnosing autism. Contemporary Pediatrics. https://www.contemporarypediatrics.com/view/fda-cleared-tool-could-assist-in-diagnosing-autism

5. Zwaigenbaum L, Bauman ML, Stone WL, Yirmiya N, Estes A, Hansen RL, McPartland JC, Natowicz MR, Choueiri R, Fein D, Kasari C, Pierce K, Buie T, Carter A, Davis PA, Granpeesheh D, Mailloux Z, Newschaffer C, Robins D, Roley SS, Wagner S, Wetherby A. Early Identification of Autism Spectrum Disorder: Recommendations for Practice and Research. Pediatrics. 2015 Oct;136 Suppl 1(Suppl 1):S10-40. doi: 10.1542/peds.2014-3667C. PMID: 26430168; PMCID: PMC9923897. https://pmc.ncbi.nlm.nih.gov/articles/PMC9923897/

6. Tirkey SS, Verma RK, et. all, Investigating the Effectiveness of Early Intervention Services for Children with Developmental Delays. Int J Acad Med Pharm 2023; 5 (5); 156-160 https://academicmed.org/Uploads/Volume5Issue5/33.%20%5B1523.%20JAMP_JESUS%20The%20Master%5D%20156-160.pdf

7. Autism Speaks. Study finds autism early intervention highly effective. 2009 Nov 29. https://www.autismspeaks.org/science-news/early-intervention-toddlers-autism-highly-effective-study-finds

8. Randall M, Egberts KJ, Samtani A, Scholten RJPM, Hooft L, Livingstone N, Sterling-Levis K, Woolfenden S, Williams K. Diagnostic tests for autism spectrum disorder (ASD) in preschool children. Cochrane Database of Systematic Reviews 2018, Issue 7. Art. No.: CD009044. DOI: 10.1002/14651858.CD009044.pub2 https://pmc.ncbi.nlm.nih.gov/articles/PMC6513463/

9. Kalb LG, Singh V, Hong JS, Holingue C, Ludwig NN, Pfeiffer D, Reetzke R, Gross AL, Landa R. Analysis of Race and Sex Bias in the Autism Diagnostic Observation Schedule (ADOS-2). JAMA Netw Open. 2022 Apr 1;5(4):e229498. doi: 10.1001/jamanetworkopen.2022.9498. PMID: 35471566; PMCID: PMC9044110. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2791527